Full Press Release Details
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis.
ARGX
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
Key Takeaway: argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis